March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Local Anti-C5 Therapy Suppresses Experimental Choroidal Neovascularization Through Reduction Of Macrophage Infiltrate
Author Affiliations & Notes
  • Jian Liu
    Academic Unit of Ophthalmology, School of Clinical Sciences, University of Bristol, Bristol, United Kingdom
  • David A. Copland
    Academic Unit of Ophthalmology, School of Clinical Sciences, University of Bristol, Bristol, United Kingdom
  • Shintaro Horie
    Academic Unit of Ophthalmology, School of Clinical Sciences, University of Bristol, Bristol, United Kingdom
  • B. Paul Morgan
    School of Medicine, Cardiff University, Cardiff, United Kingdom
  • Lindsay B. Nicholson
    Academic Unit of Ophthalmology, School of Clinical Sciences, University of Bristol, Bristol, United Kingdom
  • Andrew D. Dick
    Academic Unit of Ophthalmology, School of Clinical Sciences, University of Bristol, Bristol, United Kingdom
  • Footnotes
    Commercial Relationships  Jian Liu, None; David A. Copland, None; Shintaro Horie, None; B. Paul Morgan, None; Lindsay B. Nicholson, None; Andrew D. Dick, None
  • Footnotes
    Support  Dunhill Medical Trust and National Eye Research Centre (UK)
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 1236. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jian Liu, David A. Copland, Shintaro Horie, B. Paul Morgan, Lindsay B. Nicholson, Andrew D. Dick; Local Anti-C5 Therapy Suppresses Experimental Choroidal Neovascularization Through Reduction Of Macrophage Infiltrate. Invest. Ophthalmol. Vis. Sci. 2012;53(14):1236.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Increasing evidence demonstrates that abnormal complement activation plays a critical role in the development of choroidal neovascularization (CNV), a complex pathological process underlying the wet form of age-related macular degeneration (AMD). The present study aimed to determine the efficacy of local administration of the murine anti-C5 mAb (BB5.1) to prevent cleavage of C5 and suppress laser-induced CNV.

Methods: : CNV was induced in C57BL/6 mice by laser photocoagulation (4 laser spots/eye). The BB5.1 mAb or an isotype control antibody (25μg/eye) were administered by intravitreal injection immediately following laser burn either as a single dose treatment, or a repeated regimen with an additional injection performed on day 7. The CNV formation was assessed by isolectin B4 staining on retinal pigment epithelium (RPE)/choroid whole-mounts. Deposition of the end product of complement activation, membrane attack complex (MAC), was detected by immunostaining. Flow cytometric analysis and confocal microscopy were used to examine cell infiltrate in RPE/choroid and retina tissues. Expression of VEGF and Arginase-1 (Arg-1) mRNA in the tissues were measured by real-time PCR.

Results: : Laser photocoagulation led to disruption of Bruch’s membrane and RPE. No significant new blood vessel growth was found at the laser-induced lesion sites before day 4, and fully-developed CNV was observed after day 7. During the early stage of CNV, there were elevated Arg-1 mRNA level and significant leukocyte infiltrate in the RPE/choroid, including accumulation of amoeboid macrophages (CD11b+VEGF+) surrounding and within the lesions prior to formation of the new blood vessels. Inhibition of C5 cleavage by local BB5.1 injection markedly suppressed MAC at the peak of MAC deposition (day 4). Furthermore, reduced macrophage and neutrophil infiltration in the RPE/choroid were seen as early as 48 hours following BB5.1 injection with diminished VEGF and Arg-1 mRNA expression in the RPE/choroid on day 4. Single dose administration showed a 52% reduction in CNV volume by day 7 compared to control treatment, but suppression of CNV was not maintained with blood vessel growth evident by day 14. However, the repeated dose regimen of BB5.1 with treatments on days 0 and 7 significantly reduced CNV volume by 56% at day 14.

Conclusions: : This data demonstrates that blocking of C5 cleavage has clinical potential to reduce CNV development via inhibiting complement activation, cell infiltrate and VEGF/Arg-1 expression. Repeated administration of anti-C5 mAb may be required for effective suppression of the pathological disease, and would provide an alternative to or combined with current VEGF-targeting therapy for wet AMD.

Keywords: age-related macular degeneration • choroid: neovascularization • immunomodulation/immunoregulation 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×